Get the Stockscreener App
0.4803
1.69%
0.008
Pre-market:
.48
-0.0003
-0.06%
Century Therapeutics Inc stock is traded at $0.4803, with a volume of 2.68M.
It is up +1.69% in the last 24 hours and down -11.43% over the past month.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
See More
Previous Close:
$0.4723
Open:
$0.4713
24h Volume:
2.68M
Relative Volume:
2.90
Market Cap:
$40.80M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-0.2097
EPS:
-2.29
Net Cash Flow:
$-102.08M
1W Performance:
-12.43%
1M Performance:
-11.43%
6M Performance:
-14.23%
1Y Performance:
-60.63%
1-Day Range:
$0.435
$0.4806
1-Week Range:
$0.435
$0.575
52-Week Range:
$0.3418
$1.83
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.4803 | 40.80M | 2.24M | -136.67M | -102.08M | -2.29 |
|
ARGX
Argen X Se Adr
|
929.61 | 55.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.02 | 110.91B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
197.40 | 41.21B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
376.63 | 40.48B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
704.31 | 72.89B | 14.25B | 4.58B | 3.88B | 41.77 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
IPSC Stock Downgraded by Leerink Partners: Price Target Slashed - GuruFocus
What technical signals suggest for Century Therapeutics Inc. stockGap Up & Community Consensus Trade Alerts - newser.com
Leerink Partners Downgrades Century Therapeutics to Market Perform From Outperform, Price Target is $7 - MarketScreener
Century Therapeutics stock downgraded by Leerink Partners on lack of catalysts - Investing.com Canada
Leerink Partners Downgrades Century Therapeutics to Market Perform From Outperform - MarketScreener
What Fibonacci levels say about Century Therapeutics Inc. reboundRisk Management & Free Technical Confirmation Trade Alerts - newser.com
Analyzing drawdowns of Century Therapeutics Inc. with statistical toolsQuarterly Market Summary & AI Powered Market Entry Strategies - newser.com
What machine learning models say about Century Therapeutics Inc.July 2025 Price Swings & Accurate Intraday Trading Signals - newser.com
Century Therapeutics Inc. stock trend outlook and recovery pathWeekly Trade Recap & High Accuracy Investment Entry Signals - newser.com
Published on: 2025-11-15 03:30:02 - newser.com
Can volume confirm reversal in Century Therapeutics Inc.2025 Trading Volume Trends & Weekly High Conviction Trade Ideas - newser.com
Century Therapeutics unveils β islet program for type 1 diabetes - BioWorld MedTech
Century Therapeutics Reports Positive Q3 2025 Earnings - TipRanks
Real time pattern detection on Century Therapeutics Inc. stockIPO Watch & Safe Capital Growth Trade Ideas - newser.com
Century Therapeutics Inc. stock trendline breakdownPortfolio Growth Summary & Daily Technical Stock Forecast Reports - newser.com
Century Therapeutics unveils T1D therapy program with immune evasion tech By Investing.com - Investing.com Nigeria
Century Therapeutics Shrinks Costs But Net Loss Widens - Finimize
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Investing News Network
[8-K] Century Therapeutics, Inc. Reports Material Event | IPSC SEC FilingForm 8-K - Stock Titan
Century Therapeutics Q3 net loss widens, despite lower costs - MarketScreener
Century Therapeutics, Inc. SEC 10-Q Report - TradingView
[10-Q] Century Therapeutics, Inc. Quarterly Earnings Report | IPSC SEC FilingForm 10-Q - Stock Titan
Century Therapeutics unveils T1D therapy program with immune evasion tech - Investing.com
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes - The Manila Times
Century (NASDAQ: IPSC) unveils CNTY-813 iPSC beta islets; IND-enabling start 2025, IND 2026 - Stock Titan
Ready to Jump After Recent Trade: Century Therapeutics Inc (IPSC) - setenews.com
What does recent volatility data suggest for Century Therapeutics Inc.Stock Surge & Reliable Momentum Entry Alerts - newser.com
Is Century Therapeutics Inc a good long term investmentEconomic Data Impact & Minimal Investment Capital - earlytimes.in
Published on: 2025-11-10 05:09:59 - newser.com
How Century Therapeutics Inc. stock performs in rising dollar environment2025 Market Sentiment & Fast Entry High Yield Tips - newser.com
Century Therapeutics Inc. stock momentum explainedMarket Risk Summary & Technical Pattern Based Signals - newser.com
How to manage a losing position in Century Therapeutics Inc.2025 Institutional Moves & Short-Term Trading Alerts - newser.com
What drives Century Therapeutics Inc stock priceCapital Gains Strategies & Discover Stocks Experts Are Watching - earlytimes.in
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.99%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):